• Attovia Therapeutics released positive 12-week Phase 1b results for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis on November 5, 2026.
• A single dose delivered sustained itch relief in chronic pruritus, outperforming placebo.
• Atopic dermatitis patients showed improved skin lesions, though the itch response rate trailed placebo at Week 12.
• Treatment was generally well tolerated, with sustained biological activity supporting potential quarterly dosing.
• Two Phase 2 trials are planned for the first half of 2027, targeting approximately 300 chronic pruritus patients and 255 dermatitis patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Attovia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871735) on November 05, 2026, and is solely responsible for the information contained therein.